InNexus to Present at International Bio Ventures Conference TSX.V: IXS OTC BB: IXSBF VANCOUVER, March 18 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. is pleased to announce it has been selected to speak at the 5th Annual EC 21 Bio Ventures Conference to be held March 22-23 in London, England at the Queen Elizabeth II Conference Centre at 1:45 pm. Additionally, the Company's business plan has been selected from an international assemblage of submissions as one of three finalists for the Best in Show - Business Plan Competition being held in conjunction with the Conference. The InNexus presentation will include an overview of Super Antibody Technology, current partnership and co-development activity, recent expansion of its development program and lab facilities, and the strategic direction of the company. "The EC 21 meeting continues our exposure to the financial community while allowing our technology and business plans to be showcased before a large international audience of investors," commented Dr. Charles Morgan, President and CEO of InNexus. The Technology Vision Group LLC and Ferghana Partners Group, co-sponsors of the Business Plan "Best in Class" event, have organized the competition for life science companies to compete via their business plans and presentations. This highly competitive event utilizes a multi-disciplined panel to judge the "investment merits" of three finalists and award The 2005 EC21 BioVentures Best in Show Award. About EC 21 The mission of the European C21 BioVentures (EC21) conference is to educate all stakeholders in the bioscience industry about the trends that are driving its growth and development in the 21st century. The conference was first held in 2000 in London and has evolved into an annual gathering to explore the future of investing in biotechnology. The EC21 conference attracts leading technology experts, investors and company executives to meet informally, exchange ideas and to review the business goals of innovative new companies in the fields of biotechnology, informatics, medical devices and healthcare. Representatives in attendance include: senior executives from Big Pharma, life science companies, entrepreneurs, scientists, technology transfer experts, investment fund and asset managers, investment and commercial bankers, corporate finance specialists, equity analysts, venture capitalists, high net worth private investors, and government officials working in the area of technology and industrial development. In addition, representatives from leading service providers and the media will also attend. For more information please visit http://www.techvision.com/ec21/about About InNexus InNexus Biotechnology Inc. is an innovative antibody-driven drug development company that has developed two technology platforms, SuperAntibody(TM) and TransMAbs(TM), which respectively improve the potency of existing antibody products and create a novel class of antibody based drugs which can penetrate into cells. Both product platforms utilize unique, novel and patented methods and technologies allowing InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics to create new markets within multiple disease areas. To learn more about InNexus please visit http://www.innexusbiotech.com/ This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities. On behalf of the Board of Directors of InNexus Biotechnology, Inc. "ALTON C. MORGAN" Dr. A. Charles Morgan President Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788 The TSX Venture Exchange has neither approved nor disapproved of the information contained herein. DATASOURCE: InNexus Biotechnology, Inc. CONTACT: Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788,

Copyright